# Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC

Source: https://onco.cc/trials/nct05852990/  
OnCo record `nct05852990` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in lung cancer, run by Instituto Nacional de Cancerologia de Mexico, now recruiting.

## Summary

Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC is a phase 3, randomised interventional study registered as NCT05852990 by Instituto Nacional de Cancerologia de Mexico, with a registry enrolment figure of 28 participants, started 2022-03-01 and due to reach its primary completion in 2026-12-01. Interventions recorded: Glutamine plus L. reuteri. Conditions listed: Non-Small Cell Lung Cancer With EGFR Mutation. Primary outcome: Diarrhea toxicity; Functional Assessment of Chronic Illness Therapy. Lung eligibility wording from the registry: "* Pathologically confirmed diagnosis of NSCLC". Sites: Mexico. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT05852990
- Phase: 3
- Setting: Effect of Glutamine Plus Lactobacillus Reuteri Added to an Astringent Diet in Preventing Diarrhea Caused by Tyrosine Kinase Inhibitors (TKIs) in Patients With Advanced Non-small Cell Lung Cancer
- Sponsor: Instituto Nacional de Cancerologia de Mexico
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT05852990: https://clinicaltrials.gov/study/NCT05852990

## Connected records

- cancers: [EGFR-mutated non-small-cell lung cancer](https://onco.cc/cancers/egfr-mutant-nsclc/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05852990.json